{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:10:18Z","timestamp":1728601818072},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.gastrohep.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T15:45:15Z","timestamp":1705074315000},"page":"721-726","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective granulocyte\u2013monocyte apheresis during induction with vedolizumab in moderate\u2013severe ulcerative colitis: Experience in a tertiary hospital"],"prefix":"10.1016","volume":"47","author":[{"given":"Cristina","family":"Su\u00e1rez Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Martin-Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Mart\u00edn-Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2024.01.002_bib0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1780339","article-title":"Glucocorticoid resistance in inflammatory bowel disease","volume":"178","author":"Farrell","year":"2003","journal-title":"J Endocrinol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/17474124.2016.1123618","article-title":"Vedolizumab for the treatment of ulcerative colitis","volume":"10","author":"Stallmach","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0165","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0185","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice \u2013 a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0190","doi-asserted-by":"crossref","first-page":"1199212","DOI":"10.1111\/apt.13813","article-title":"Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease \u2013 a prospective multicenter observational study","volume":"44","author":"Stallmach","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0195","first-page":"5156","article-title":"The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion","volume":"13","author":"Song","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17474124.2022.2100759","article-title":"Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis","volume":"16","author":"Bamias","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0205","first-page":"765","article-title":"Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus adalimumab: therapeutic outcomes in 5 cases with refractory Crohn's disease","volume":"6","author":"Ozeki","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0210","doi-asserted-by":"crossref","first-page":"884","DOI":"10.14740\/jocmr2333w","article-title":"Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis","volume":"7","author":"Tanida","year":"2015","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/1744-9987.12697","article-title":"Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus ustekinumab in patients with refractory Crohn's disease","volume":"22","author":"Tanida","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14740\/jocmr4037","article-title":"Combination therapy with tofacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction therapy for refractory ulcerative colitis","volume":"12","author":"Tanida","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0225","doi-asserted-by":"crossref","first-page":"510","DOI":"10.14740\/jocmr4625","article-title":"Combination therapy with ustekinumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis","volume":"13","author":"Tanida","year":"2021","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.dld.2018.01.124","article-title":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-alpha drug failure","volume":"50","author":"Saez-Gonzalez","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0235","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.dld.2018.05.001","article-title":"Response to \u201cThe combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous anti-TNF alfa failure\u201d","volume":"50","author":"Scrivo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1744-9987.12485","article-title":"Granulocyte\u2013monocyte apheresis as an adjuvant therapy to anti-tumor necrosis factor drugs for ulcerative colitis","volume":"21","author":"Rodriguez-Lago","year":"2017","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0245","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jca.21746","article-title":"The combination of granulocyte\u2013monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis?","volume":"34","author":"Rodr\u00edguez-Lago","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0250","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2169\/internalmedicine.5302-20","article-title":"Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis","volume":"59","author":"Nakamura","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0255","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0260","doi-asserted-by":"crossref","first-page":"763e86","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.15592","article-title":"Systematic review with meta-analysis: mortality in acute severe ulcerative colitis","volume":"51","author":"Dong","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/gut.2010.216895","article-title":"Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers","volume":"60","author":"Travis","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.gastrohep.2018.04.007","article-title":"Granulocyte and monocyte apheresis in inflammatory bowel disease: the patients\u2019 point of view","volume":"41","author":"Rodr\u00edguez-Lago","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0280","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/gutjnl-2021-324868","article-title":"Residual homing of \u03b14\u03b27-expressing \u03b21+PI16+regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab","volume":"71","author":"Becker","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0285","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3748\/wjg.14.1521","article-title":"Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis","volume":"14","author":"Cuadrado","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.01.002_bib0290","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2017.12.030","article-title":"Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte\/monocyte apheresis: a case series","volume":"103","author":"Yokoyama","year":"2017","journal-title":"Cytokine"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T22:29:03Z","timestamp":1728599343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570524000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0210570524000189"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.01.002","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective granulocyte\u2013monocyte apheresis during induction with vedolizumab in moderate\u2013severe ulcerative colitis: Experience in a tertiary hospital","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}